Sonya Krishnan, MD

Baltimore, Maryland
Role: 
Faculty
Assistant Professor
Sonya Krishnan, MD

Sonya Krishnan, MD, is Assistant Professor in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. Her research interests include host biomarkers of HIV/TB and TB outcomes with particular interest in understanding inflammation pathways, their impacts and potential therapies.  

Dr. Krishnan grew up in Minnesota and completed her undergraduate studies at Carleton College, becoming involved in HIV research while studying abroad in Tanzania. After college she spent two years at the NIH studying predictors of IRIS as well as inflammatory markers in HIV-infected elite controllers with Dr. Irini Sereti. She then completed her MD at George Washington University and subsequently moved to Baltimore for internal medicine residency at Johns Hopkins. During residency she continued to pursue her interest in global health, studying Chagas Cardiomyopathy in Bolivia with Dr. Gilman via a Paul S. Lietman Global Travel Grant. She completed her clinical infectious diseases fellowship at Johns Hopkins School of Medicine in 2022.

Innovative modelling for predicting TB treatment outcomes in global cohorts

Post Date: 
2021-12-19
Our overarching hypothesis is that clinical and laboratory risk factors for the adversity be treatment outcomes of failure, recurrence and mortality are heterogeneous and time-dependent. Precision medicine approaches supported by Machine learning techniques that overcome the limitations of...

Isoniazid adherence improves survival and incident tuberculosis at 96 weeks among adults initiating antiretroviral therapy with advanced HIV in multiple high burden settings

Post Date: 
2022-07-03
   |   
Countries: 
India
Publication: 
Open Forum Infectious Diseases
Background People with human immunodeficiency virus (HIV) and advanced immunosuppression initiating antiretroviral therapy (ART) remain vulnerable to tuberculosis (TB) and early mortality. To improve early survival, isoniazid preventive therapy (IPT) or empiric TB treatment have been evaluated;...

Diagnostic biomarkers for active tuberculosis: Progress and challenges

Post Date: 
2022-06-20
   |   
Countries: 
India
Publication: 
EMBO Molecular Medicine
Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb)...

Integrative multi-omics reveals serum markers of tuberculosis in advanced HIV

Post Date: 
2021-06-08
Publication: 
Frontiers in Immunology
Tuberculosis (TB) accounts for disproportionate morbidity and mortality among persons living with HIV (PLWH). Conventional methods of TB diagnosis, including smear microscopy and Xpert MTB/RIF, have lower sensitivity in PLWH. Novel high-throughput approaches, such as miRNAomics and metabolomics,...